BIODRIBIN

DRUG3 trials

Sponsors

Medical University Of Lodz, Instytut Psychiatrii I Neurologii, Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Conditions

Acute Myeloid LeucaemiaAcute myeloid leukemiaMultiple sclerosis secondary progressive formmyelodysplastic syndromes

Phase 2

Assessment of Tolerance and Effectiveness of Total Body Irradiation and Cladribine Before Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Active, not recruitingCTIS2024-517477-24-00

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut BadawczyAcute myeloid leukemia, myelodysplastic syndromes

Start: 2022-02-17Target: 40Updated: 2025-04-02

CLASP MS: The study evaluating the efficacy and safety of Polish cladribine in the treatment of patients with secondary progressive multiple sclerosis - a phase 2, randomized, double-blind, placebo-controlled trial.

Not yet recruitingCTIS2024-516992-33-02

Instytut Psychiatrii I NeurologiiMultiple sclerosis secondary progressive form

Target: 188Updated: 2025-01-30

Phase 3

MAGIC AML - Multiarm, Multicenter, RAndomized, Molecularly-GuIded Controlled Trial of Personalized Treatment Strategy - of Acute Myeloid Leukemia

RecruitingCTIS2023-503394-37-00

Medical University Of LodzAcute Myeloid Leucaemia

Start: 2024-10-23Target: 520Updated: 2025-10-15